Osimertinib: 14 agencies, 2016–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “The treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC).”, while PBAC (Australia) recorded not recommended for “Locally advanced (Stage III) or metastatic (Stage IV) epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC)”.
Assessment has run over 10 years, from 5 May 2016 at AWMSG (Wales) to 21 May 2026 at NICE (England).
ZIN (Netherlands) changed its position: not recommended on 7 Nov 2018, restricted by 15 Apr 2026, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for osimertinib.
The file is active: 29 of 65 records date from 2023 or later.
The programme is broad: 15 distinct indication wordings are recorded for osimertinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
8 of these 65 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess osimertinib, on 5 May 2016; CIPM (Spain) did not open a file until 7 Jul 2022 — a wide spread of 6.2 years between the earliest and latest system to look at it.
The record arrives in waves: 11 separate years each carry two or more decisions, spread across 11 years in total.
13 of the 14 agencies here assessed osimertinib more than once, PBAC (Australia) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
osimertinib has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for osimertinib reads 30 recommended, 10 restricted, 8 not recommended and 5 deferred to NICE, with 12 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 29 Apr 2026 | Maintenance treatment of locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (NSCLC) in ad… | excluded, NICE appraised | source |
| ZIN (Netherlands) | 15 Apr 2026 | Advies - alleen vergoeden na prijsdaling osimertinib (Tagrisso®) in combinatie met pemetrexed en chemotherapie voor de b… | reimburse only after price negotiation (sluis) | source |
| SMC (Scotland) | 13 Apr 2026 | For treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose di… | accepted | source |
| NYE METODER (Norway) | 15 Mar 2026 | Kombinasjon med pemetreksed og platinabasert kjemoterapi som førstelinjebehandling hos voksne pasienter med avansert NSC… | introduced | source |
| DMC (Denmark) | 29 Oct 2025 | Voksne patienter med lokalt avanceret, inoperabel NSCLC, hvis tumorer har EGFR-exon 19-deletioner eller exon 21 (L858R) … | Ikke anbefalet | source |
60 further decisions for osimertinib, across 14 agencies, are not shown here. They include the most recent record on file, 21 May 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 48 further source documents.
Related molecules
- pralsetinib — divergent outcome (recommended vs not recommended) on a shared indication
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 65 decisions for osimertinib from 14 agencies, 2016 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.